New appointments to the Lek Supervisory Board and Board of Management
The Supervisory Board of Lek, a new Sandoz company, at its latest meeting on July 6 2005 appointed a new member to the Board of Management. The Lek Shareholders’ Assembly also appointed two new members to the Supervisory Board at the end of June. The new member of the Board of Management is Ksenija Butenko Černe, who joins the formerly three-member Board of Management. The newly appointed members of the Supervisory Board are Dr. Andreas Strűngmann and Markus Delfosse.
Ksenija Butenko Černe is a law school graduate who has worked at Lek since 1994. Since 2001 she has been Executive Director in charge of the Legal Affairs department. On being appointed to the Board of Management she will assume the responsibility for managing and ensuring the legal alignment of Lek’s operations as a corporate citizen and member of the Novartis/Sandoz group. She will also retain her present responsibilities as Director of Legal Affairs and Sandoz’s Lead Legal Counsel for the Central and Eastern Europe region on the global level.
The newly appointed members of the Supervisory Board Dr. Andreas Strűngmann and Markus Delfosse replace outgoing members Christian Seiwald and Hubert Hirzinger. Markus Delfosse, who is responsible for Technical Operations at Sandoz, was appointed the new Deputy President of the Lek Supervisory Board.
***
Lek, a new Sandoz company, is an international pharmaceutical company which operates as a business center on the markets of Central and Eastern Europe, Southeastern Europe and the CIS region, and also markets its products successfully on the US market, in the EU and elsewhere around the world. Lek creates value through the development, manufacturing and sales of pharmaceutical products, active pharmaceutical ingredients and biopharmaceutical products. Lek employs about 4,186 people in various regions and achieved total sales of USD 746.5 million in 2004. For further information please consult http://www.lek.si
Sandoz, a Novartis company, is a leading global supplier of high-quality generic pharmaceuticals. Headquartered in Vienna, Austria, Sandoz is a Retail Generics company operating also two Business Units with specific strategic focus – Industrial Products and Biopharmaceuticals. In 2004, Sandoz achieved sales of USD 3.045 billion, employs about 13,400 people and operate in over 120 countries around the world.
Novartis AG (NYSE: NVS) is a world leader in pharmaceuticals and consumer health. In 2004, the Group’s business achieved sales of USD 28.2 billion and a net income of USD 5.8 billion. The Group invested approximately USD 4.2 billion in R&D. Headquartered in Basel, Switzerland, Novartis Group companies employ about 81,400 people and operate in over 140 countries around the world. For further information, please consult http://www.novartis.com
This press release contains certain “forward-looking statements and conclusions” based on projections of Lek’s future business operations. These estimates are derived from the best information currently available. In case these forecasts prove unreliable, the actual results could prove different from those projected.
- * *
For further information contact:
Špela Jurak
Corporate Communications
Lek Pharmaceuticals d.d.
Phone: + 386 1 580 22 43
Fax: + 386 1 580 24 32
communications.lek@sandoz.com